Jocelyn Voell

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2”.

A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2

Annals of Internal Medicine(2024)10.7326/m23-2593

N/A

0.376DataRank · unranked

6 citations

Jing Wang, Kay M. Tomashek, Tyler Bonnett, Kanal Singh, Vincent C. Marconi +16 more

Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

Clinical Infectious Diseases(2021)10.1093/cid/ciab695

N/A

0DataRank · unranked

17 citations

Shannon Gallagher, Rekha R. Rapaka, Richard T. Davey, Sarah B. Doernberg, Robert Grossberg +11 more

Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad290

N/A

0DataRank · unranked

2 citations

Noreen A. Hynes, Corri B. Levine, Katherine Yang, Zanthia Wiley, Nikolaus Jilg +37 more